Abstract
Keratoconus is characterized by progressive primary corneal ectasia, resulting in decreased visual acuity in young adults and remains a leading indication for corneal transplantation surgery worldwide. Collagen crosslinking treatment of the cornea, pretreated with riboflavin drops, with UVA light has been described as a revolutionary new treatment that is effective in arresting the progression of keratoconus and results in corneal strengthening. This review discusses current collagen crosslinking treatment for keratoconus including the basic changes induced in the cornea, results of various clinical trials and complications involved. Data available are conclusive of the fact that collagen crosslinking treatment of progressive keratoconus using the photosensitizer riboflavin and UVA light of 370 nm wavelength is effective in the stabilization of progressive keratoconus.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call